DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/nj8898/mgn1703) has announced the addition of the "MGN1703 (Colorectal Cancer) - Forecast and Market Analysis to 2023" report to their offering.
Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic.
Mologen AG is developing MGN1703 as a maintenance therapy for the treatment of advanced CRC patients with disease control after first-line induction chemotherapy treatment with or without biological treatment. The developer launched the pivotal Phase III IMPALA European trial to evaluate this drug in September, 2014. This randomized, multicenter, open-label trial is investigating MGN1703 as a monotherapy compared to investigator choice maintenance treatment, namely treatment break, reduced treatment, and continued treatment, and is due to begin enrollment of an estimated total 540 patients in August 2014.
Scope
- Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on MGN1703 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for MGN1703 for the top five countries from 2013 to 2023.
- Sales information covered for France, Germany, Italy, Spain and the UK.
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Unmet Need and Opportunity
7 Pipeline Assessment
8 MGN1703
9 Appendix
For more information visit http://www.researchandmarkets.com/research/nj8898/mgn1703
